Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs

Innovative trial will use psilocybin to target relapse in opioid addiction

Filament Health Announces Issuance Of Common Shares To Negev Capital Investments Limited Pursuant To Advisory Agreement

Filament Health Announces Second Quarter 2024 Financial Results And Operational Highlights